Search research articles
Contact Us
Filters
Showing results (121-130 of 130) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 130 results.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Journal for Immunotherapy of Cancer
|
March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
Michael A Postow, Peter D Zang, Sumanta K Pal, et al.
Journal for Immunotherapy of Cancer
|
October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Craig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Cancer Immunology, Immunotherapy : CII
|
February 13, 2019
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
Linh T Nguyen, Samuel D Saibil, Valentin Sotov, et al.
Nature Medicine
|
January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trial
David S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Journal for Immunotherapy of Cancer
|
January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Aljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Cancers
|
January 10, 2026
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus
Juan Alban, R Christopher Bowen, David A Reichstein, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 130) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 130 results.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Journal for Immunotherapy of Cancer
|
March 15, 2019
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
Derek L Clouthier, Scott C Lien, S Y Cindy Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Journal for Immunotherapy of Cancer
|
March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
Michael A Postow, Peter D Zang, Sumanta K Pal, et al.
Journal for Immunotherapy of Cancer
|
October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Craig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Cancer Immunology, Immunotherapy : CII
|
February 13, 2019
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
Linh T Nguyen, Samuel D Saibil, Valentin Sotov, et al.
Nature Medicine
|
January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trial
David S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Journal for Immunotherapy of Cancer
|
January 20, 2021
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Aljosja Rogiers, Ines Pires da Silva, Chiara Tentori, et al.
Cancers
|
January 10, 2026
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus
Juan Alban, R Christopher Bowen, David A Reichstein, et al.
Page
of 13